Charles-André Brouwers

Charles-André Brouwers has a wealth of work experience, beginning in 1990 as a Consultant with The MAC Group. In 1993, they moved to Gemini Consulting as a Project Manager, then to Bossard Gemini Consulting as Vice President - Head of Life Sciences Division France/Benelux in 1997. In 1999, they became Vice President - Head of Life Sciences Division at Cap Gemini, then Senior Partner and Managing Director at Boston Consulting Group (BCG) in 2000. In 2021, they became an Independent Director at OncoDNA, and in 2022 they were appointed as Founder and Managing Partner of Galileo Life Sciences, President of BelCham, and Managing Director, Investment Banking at Galileo Global Securities LLC, as well as an Independent Director at Elysia-raytest.

Charles-André Brouwers obtained a MSIA/MBA in Business Administration from Carnegie Mellon University - Tepper School of Business between 1988 and 1990. Prior to that, they obtained an Ir. Civ Elec. in Electronic & Computer Engineering from the University of Liège between 1981 and 1986. Additionally, they have obtained certifications from FINRA including the S63 - Uniform Securities Agent State Law Examination, S79TO - Investment Banking Registered Representative Examination, and SIE - Securities Industry Essentials Examination.